Appearance：White or almost white, crystalline powder；
Heavy metals：Not exceeding 20ppm.
Related substances： Impurity J: ≤10ppm， Impurity K: ≤50ppm，Impurity F: ≤0.05%， any other impurity: ≤0.05%.
Appearance: Crystalline powder ranging from off white to slightly yellow green in color;
Melting point: 198-202 ℃, melting and decomposing simultaneously.
Regarding substances: The maximum single impurity shall not exceed 0.1%; The total magazine shall not exceed 1.0%;
Chloride: not exceeding 0.1%;
Dry weight loss: not exceeding 1.0%;
Burning residue: not exceeding 0.1%;
Heavy metals: not exceeding 20ppm;
Arsenic salt: not exceeding 0.0004%
Content: not less than 98.5%.
Indications: To provide symptomatic treatment for relieving pain and swelling in various types of arthritis and soft tissue lesions.
Appearance: White crystals or colorless crystalline powder;
Acidity pH: 5.0-6.5;
Solution appearance: Solution S is clear and colorless;
Sulfuric acid ash content: not exceeding 0.1%;
Dry weight loss: not exceeding 0.5%;
Related substances: not exceeding 0.05%;
Aminobenzoic acid: not exceeding 0.5%;
Iron salt: not exceeding 0.001%;
Heavy metals: not exceeding 5PPM;
Content: should be between 99.0% and 101.0%.
Appearance: This product is a white to slightly yellow powder or crystalline powder; Odorless.
Melting point: The melting point of this product is 148.5~152.0 ℃.
Chloride: not exceeding 0.005%.
Dry weight loss: not exceeding 0.5%.
Burning residue: not exceeding 0.1%.
Heavy metals: not exceeding 10ppm.
Regarding substances: maximum single impurity ≤ 0.5%, total impurity ≤ 0.5%.
Content: not less than 99.0%.
Appearance: This product is a colorless to pale yellow liquid.
Density: approximately 1.243 g/mL~1.3 ± 0.1 g/cm ³.
Moisture content: not exceeding 0.5%.
Regarding substances: maximum single impurity ≤ 0.5%, total impurity ≤ 0.5%.
Content: not less than 99.0%.
Appearance: White or off white crystalline powder
Melting point: 153~158 ℃
PH value: 3.5~5.5
Regarding substances: individual impurities should not exceed 0.10%, and total impurities should not exceed 1.0%;
Dry weight loss: not exceeding 0.5%;
Burning residue: not exceeding 0.1%;
Heavy metals: not exceeding 20 parts per million;
Optical isomers: not exceeding 1.0%;
Content: should be between 98.5% and 101.0%.
Indications: monotherapy (not in combination with levodopa) for idiopathic Parkinson’s disease or adjuvant therapy (in combination with levodopa) for Parkinson’s disease with dose fluctuations.
Appearance：Almost white or almost white powder.
Solubility：Practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol (96 per cent). It dissolves in dilute acid solutions.
Appearance of solution：The solution is clear and colourless.
Related substances：
Impurity A ,B,C,D,E ≤ 0.2 % ;Impurity K ≤ 0.15 % ;unspecified impurities≤ 0.10 % ;total≤ 0.3%;
Loss on drying：Maximum 0.5 percent
Sulfated ash：Maximum 0.1 percent
Assay：99.0 per cent to 101.0% per cent（dried substance).
Used for treating acute and chronic schizophrenia. Especially for positive and negative symptoms and their accompanying emotional symptoms (such as anxiety, depression, etc.), it has good therapeutic effects. It can also alleviate emotional symptoms associated with schizophrenia. For patients who are effectively treated in the acute phase, this product can continue to exert its clinical efficacy during maintenance treatment.
Appearance: White crystalline powder
Solubility: soluble in chloroform, DMSO (87 mg/ml, 25 ℃), water (<1 mg/ml, 25 ℃), and ethanol (<1 mg/ml, 25 ℃).
Melting Point：228-229°C
Specific rotation: -38 to -42 °
Content: 99%
Usage: Rivaroxaban is a highly selective oral medication that directly inhibits factor Xa. Inhibition of factor Xa can interrupt the endogenous and exogenous pathways of coagulation cascade, inhibiting the production of thrombin and thrombus formation. Rivaroxaban does not inhibit thrombin (activating factor II), nor has it been proven to have an effect on platelets. Rivaroxaban is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).
Appearance: White to off white or light yellow powder; It smells bad.
Solubility: This product is highly soluble in anhydrous ethanol, acetonitrile, and 0.1mol/L hydrochloric acid solution, soluble in water and N, N-dimethylformamide, and almost insoluble in ether.
Specific rotation: from+28.5 ° to+32.0 °;
The clarity of the solution should not exceed the turbidity of standard solution No.1;
The color of the solution should not be darker than the yellow standard colorimetric solution No. 2;
Alkalinity: The pH value should be between 8.9 and 9.5
Moisture content: not exceeding 3.0%
Burning residue: not exceeding 0.1%
Heavy metals: not exceeding 10 parts per million
Regarding substances: Impurity A shall not exceed 0.2%, Impurity B shall not exceed 0.3%, other impurities shall not exceed 0.1%, and total impurities shall not exceed 1.0%;
Content: should be between 99.0% and 101.0%.
Indications:
As an adjuvant for general anesthesia, perform routine endotracheal intubation and relax skeletal muscles during surgery or mechanical breathing to facilitate surgical operations and improve gas exchange in the body. Suitable for general anesthesia, relaxing skeletal muscles, and endotracheal intubation.
Appearance: White crystalline powder;
Specific rotation: should be+32.0~36.0 º;
Dry weight loss: not exceeding 0.20%;
Chromatographic purity: not less than 98.0%.
Appearance: This product is a white or off white crystalline powder;
Specific rotation: should be+82 º to+88 º;
Related substances: Impurity EPAO should not exceed 0.5%; Isomers shall not exceed 0.1%; Other impurities must not exceed 1.8%, why not exceed 2.5%.
Morpholine: should be less than 2.0%;
Moisture content: should not exceed 0.5%;
Dry weight loss: should not exceed 0.5%;
Burning residue: should not exceed 0.1%;
Content: not less than 98.0%.
Appearance: White to off white solid;
Dry weight loss: not exceeding 0.20%;
Content: not less than 90.0%.
No products in the cart.